CMMB

Chemomab Therapeutics Ltd.

There isn't enough reported data to score CMMB yet.

CMMB Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

CMMB's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

CMMB PE Valuation

CMMB has no meaningful PE right now: it lost money over the past year.

CMMB Forward outlook

MetricOutlook
--
Losses shrinking
--
--
Limited
High

Analysts expect CMMB's losses to shrink, with revenue holding steady.

CMMB Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $1.40 on Nov 12.

There is not enough scenario data to assess CMMB's risk to reward.

CMMB Earnings Per Share

Q2 2025: $-2.37Q3 2025: $-1.85Q4 2025: $-1.46Q1 2026: $-1.10Q2 2026: $-1.02
Q2 2025: $-2.37Q3 2025: $-1.85Q4 2025: $-1.46Q1 2026: $-1.10Q2 2026: $-1.02
QuarterTTM EPSYoY
Q2 2026-$1.02+$1.35

CMMB is still losing money, but far less than before: $1.02 per share over the past year, against $2.37 at its worst in mid-2025.

CMMB Quarterly Revenue

Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0

CMMB's revenue is shrinking: $0 last quarter.

CMMB Free Cash Flow

Q3 2023: −$5MQ4 2023: −$4MQ1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: −$11MQ1 2026: $0Q2 2026: $0
Q3 2023: −$5MQ4 2023: −$4MQ1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: −$11MQ1 2026: $0Q2 2026: $0
QuarterFree cash flowYoY
Q2 2026$0$0
Q1 2026$0$0
Q4 2025-$11.2M-$11.2M
Q3 2025$0$0
Q2 2025$0$0
Q1 2025$0$0
Q4 2024$0+$3.9M
Q3 2024$0+$5.1M

CMMB has burned cash in most quarters: −$11M over the past year, against $0 the year before.

CMMB Total Shares

Q3 2024: 4MQ4 2024: 5MQ1 2025: 6MQ2 2025: 6MQ3 2025: 6MQ4 2025: 8MQ1 2026: 8MQ2 2026: 8M
Q3 2024: 4MQ4 2024: 5MQ1 2025: 6MQ2 2025: 6MQ3 2025: 6MQ4 2025: 8MQ1 2026: 8MQ2 2026: 8M
PeriodChange %Net change
Quarterly+0.3%+24.4K shares
1 year+38%+2.2M shares

CMMB has 8M diluted shares, up 38% from a year ago.

CMMB Net Leverage

CMMB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

CMMB Weekly Momentum

MetricValueStatus
RSI43.3Neutral
Stochastic18.0Oversold

CMMB's weekly RSI is 43 (neutral) and its Stochastic is 18 (oversold).

CMMB PE vs Healthcare Sector

CMMB has no meaningful PE right now: it lost money over the past year.

CMMB Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1.390.7% above
20 week MA$1.8123% below
50 week MA$1.7721% below
100 week MA$3.3458% below
200 week MA$4.0365% below

CMMB has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 65% below its 200-week average.

CMMB Yearly ROI

YearStart priceEnd priceROI
2020$90.9$141.4+56%
2021$141.4$30.2-79%
2022$30.2$9.44-69%
2023$9.44$2.04-78%
2024$2.04$8.04+294%
2025$8.04$1.80-78%
2026 YTD$1.80$1.40-22%

CMMB's yearly returns have swung widely, from +294% in 2024 to −79% in 2021. It's down 22% so far in 2026.

Give your agent the market.

Get API key